Kristina Callis Duffin, MD, MS

Journal Article

1. Strober B, Duffin KC, Lebwohl M, Sima A, Janak J, Patel M, Photowala H, Garg V, Bagel J (2023). Impact of psoriasis disease severity and special area involvement on patient-reported outcomes in the real world: an analysis from the CorEvitas psoriasis registry. J Dermatolog Treat, 35(1), 2287401. (Read full article)
2. Liao W, Armstrong AW, Duffin KC (2024). GRAPPA Debate: Targeted Small Molecules Versus Biologics as First-Line Systemic Therapy After Conventional Therapy for Moderate-to-Severe Psoriasis. J Rheumatol, 51(Suppl 2), 89-92. (Read full article)
3. Carroll C, Aalsteinsson J, Prouty M, Duffin KC, Krueger GG, Walsh JA, Feng BJ (2024). Measuring Psoriasis Severity at Home. J Vis Exp, (205). (Read full article)
4. Chat VS, Ellebrecht CT, Kingston P, Bell S, Gondo G, Cordoro KM, Desai SR, Duffin KC, Feldman SR, Garg A, Gelfand JM, Gladman D, Green LJ, Gudjonsson J, Han G, Hawkes JE, Kircik L, Koo J, Langley R, Lebwohl M, Michael Lewitt G, Liao W, Martin G, Orbai AM, Reddy SM, Richardson V, Ritchlin CT, Schwartzman S, Siegel EL, Van Voorhees AS, Wallace EB, Weinberg JM, Winthrop KL, Yamauchi P, Armstrong AW (2024). Vaccination Recommendations for Adults Receiving Biologics and Oral Therapies for Psoriasis and Psoriatic Arthritis: Delphi Consensus from the Medical Board of the National Psoriasis Foundation. J Am Acad Dermatol. (Read full article)
5. Garg A, Noe MH, Anadkat MJ, Armstrong A, Bhutani T, Farberg A, Han G, Hawkes JE, Lebwohl M, Rekhtman S, Song EJ, Strunk A, Duffin KC (2023). Development of the Generalized Pustular Psoriasis Clinical Assessment Tool. J Am Acad Dermatol, 90(1), 192-195. (Read full article)
6. Rhoads JLW, Malatestinic WN, Burge R, Ganz ML, Duffin KC (2023). Factors Associated With Treatment Escalation for Psoriasis: An Analysis of Electronic Health Records Data. J Psoriasis Psoriatic Arthritis, 9(1), 5-15. (Read full article)
7. Strober B, Ferris L, Duffin KC, Janak JC, Sima AP, Eckmann T, Patel M, Photowala H, Garg V, Armstrong A (2023). Real-World Effectiveness of Risankizumab in Patients with Moderate-to-Severe Psoriasis using the CorEvitas Psoriasis Registry. J Am Acad Dermatol. (Read full article)
8. Walsh JA, Carroll C, Callis Duffin K, Wang J, Krueger GG, Feng BJ (2023). PAPRIKA: A Question Bank for Assessing Psoriatic Arthritis Risk in Individuals of Diverse Ancestries. Arthritis Care Res (Hoboken), 76(3), 421-425. (Read full article)
9. Callis Duffin K, Hwang ST, Krueger JG (2023). Advances and Controversies in Our Understanding of Guttate and Plaque Psoriasis. J Rheumatol. (Read full article)
10. Ng BCK, Jadon D, Adebajo A, Ayan G, Callis Duffin K, Chandran V, Coates LC, DAgostino MA, de Vlam K, Deodhar A, Eder L, Garg A, Gladman DD, Goel N, Gottlieb AB, Husni ME, Katz A, Kavanaugh A, Lubrano E, Mease PJ, Merola JF, Nash P, Ogdie A, Pennington SR, Perez-Chada LM, Proft F, Rosen CF, Savage L, Goldenstein-Schainberg C, Siebert S, Soriano ER, Steinkoenig I, Tillett W, Armstrong AW, FitzGerald O (2023). Proceedings of the GRAPPA 2022 Executive Retreat. J Rheumatol. (Read full article)
11. Armstrong AW, Fitzgerald T, McLean RR, Teeple A, Uy JP, Olurinde M, Rowland K, Guo L, Shan Y, Callis Duffin K (2023). The Effectiveness of Guselkumab by BMI Category Among Patients with Moderate-to-Severe Plaque Psoriasis in the CorEvitas Psoriasis Registry. Adv Ther, 40(5), 2493-2508. (Read full article)
12. Burden AD, Bachelez H, Choon SE, Marrakchi S, Tsai TF, Turki H, Morita A, Lebwohl MG, Bissonnette R, Zheng M, Anadkat MJ, Alexander AN, Tang M, Thoma C, Duffin KC (2023). The Generalized Pustular Psoriasis Physician Global Assessment (GPPGA) score: online assessment and validation study of a specific measure of GPP disease activity. Br J Dermatol. (Read full article)
13. Armstrong AW, Fitzgerald T, McLean RR, Teeple A, Uy JP, Olurinde M, Rowland K, Guo L, Shan Y, Callis Duffin K (2023). Real-World Effectiveness of 9–12 Months of Guselkumab Therapy among Patients with Moderate-to-Severe Plaque Psoriasis in the CorEvitas Psoriasis Registry. Dermatol Ther (Heidelb), 13(2), 629-640. (Read full article)
14. Armstrong AW, Fitzgerald T, McLean RR, Teeple A, Uy JP, Olurinde M, Rowland K, Guo L, Shan Y, Callis Duffin K (2023). Effectiveness of Guselkumab Therapy among Patients with Plaque Psoriasis with Baseline IGA Score ≥ 2 in the CorEvitas Psoriasis Registry. Dermatol Ther (Heidelb), 13(2), 487-504. (Read full article)
15. Gold LS, Papp K, Pariser D, Bhatia N, Sofen H, Albrecht L, Gooderham M, Duffin KC, Chen M, Paris M, Cheng S, Picard H, Wang Y, Green L (2023). Efficacy and safety of apremilast in patients with mild-to-moderate psoriasis up to 32 weeks: Results from the extension phase of the randomized, phase 3 ADVANCE trial. J Am Acad Dermatol, 88(2), 430-433. (Read full article)
16. Coates LC, Soriano ER, Corp N, Bertheussen H, Callis Duffin K, Campanholo CB, Chau J, Eder L, Fernndez-vila DG, FitzGerald O, Garg A, Gladman DD, Goel N, Helliwell PS, Husni ME, Jadon DR, Katz A, Laheru D, Latella J, Leung YY, Lindsay C, Lubrano E, Mazzuoccolo LD, Mease PJ, OSullivan D, Ogdie A, Olsder W, Palominos PE, Schick L, Steinkoenig I, de Wit M, van der Windt DA, Kavanaugh A, Campanholo CB, Fitzgerald O, Gladman D, Helliwell P, Husni ME, Laheru D, Leung YY, Mazzuoccolo LD, Mease PJ, Ogdie A, Palominos PE (2022). Author Correction: Group for Research and Assessment of Psoriasis and Psoriatic Arthritis (GRAPPA): updated treatment recommendations for psoriatic arthritis 2021 (Nature Reviews Rheumatology, (2022), 18, 8, (465-479), 10.1038/s41584-022-00798-0). Nat Rev Rheumatol, 18(12), 734. (Read full article)
17. Hopkins ZH, Kuceki G, Taliercio VL, Snyder AM, Stoddard GJ, Duffin KC, Hess R, Secrest AM (2022). Evaluation of Skindex-16 construct validity in routinely collected psoriasis data: a retrospective analysis of the relationship between overall physician global assessment scores and Skindex-16 and measure discordance. Arch Dermatol Res. (Read full article)
18. Coates LC, Soriano ER, Corp N, Bertheussen H, Callis Duffin K, Campanholo CB, Chau J, Eder L, Fernndez-vila DG, FitzGerald O, Garg A, Gladman DD, Goel N, Helliwell PS, Husni ME, Jadon DR, Katz A, Laheru D, Latella J, Leung YY, Lindsay C, Lubrano E, Mazzuoccolo LD, Mease PJ, OSullivan D, Ogdie A, Olsder W, Palominos PE, Schick L, Steinkoenig I, de Wit M, van der Windt DA, Kavanaugh A, Campanholo CB, Fitzgerald O, Gladman D, Helliwell P, Husni ME, Laheru D, Leung YY, Lubrano E, Mazzuoccolo LD, Mease PJ, Ogdie A, Palominos PE (2022). Group for Research and Assessment of Psoriasis and Psoriatic Arthritis (GRAPPA): updated treatment recommendations for psoriatic arthritis 2021. Nat Rev Rheumatol, 18(8), 465-479. (Read full article)
19. Takeshita J, Chau J, Duffin KC, Goel N (2022). Promoting Diversity, Equity, and Inclusion for Psoriatic Diseases. J Rheumatol, 49(6), 48-51. (Read full article)
20. Armstrong AW, Reddy RM, FitzGerald O, Duffin KC, Helliwell PS, Mease PJ, Kavanaugh A, Merola JF, Tillet W, Wit Md (2022). 2021 GRAPPA Meet the Experts Session: A Summary of Presentations. J Rheumatol, 49(6), 32-36. (Read full article)
21. Duffin KC, Gladman DD, Goel N, Gottlieb AB, FitzGerald O, McFarland LV (2022). Prologue: 2021 Annual Meeting of the Group for Research and Assessment of Psoriasis and Psoriatic Arthritis (GRAPPA). J Rheumatol, 49(6), 1-3. (Read full article)
22. Ogdie A, Lindsay CA, Mease PJ, Duffin KC, Rosen CF, Siebert S (2022). Challenges in the Diagnosis and Assessment of Psoriatic Arthritis. J Rheumatol, 49(6), 64-67. (Read full article)
23. Noe MH, Wan MT, Mostaghimi A, Gelfand JM, Agnihothri R, Armstrong AW, Bhutani T, Bridges A, Brownstone N, Butt M, Duffin KPC, Carr C, Creadore A, Deniro KL, Desai S, Dominguez AR, Duffy EK, Fairley JA, Femia A, Gudjonsson JE, Kaffenberger JA, Katz KL, Le ST, Martinez E, Maverakis E, Myers B, Naik HB, Nelson CA, Ortega-Loayza AG, Plovanich ME, Rangel LK, Ravi V, Reddy VD, Saleh JZ, Kirby JS, Sandhu JK, Shakshouk H, Shields BE, Sharif-Sidi Z, Smith J, Steahr A, Toussi A, Wanat KA, Wang B, Wei BM, Weinhammer A, Worswick SD, Yang A (2022). Evaluation of a Case Series of Patients with Generalized Pustular Psoriasis in the United States. JAMA Dermatol, 158(1), 73-78. (Read full article)
24. Walsh JA, Callis Duffin K, Van Voorhees AS, Chakravarty SD, Fitzgerald T, Teeple A, Rowland K, Uy J, McLean RR, Malley W, Cronin A, Merola JF (2022). Demographics, Disease Characteristics, and Patient-Reported Outcomes Among Patients with Psoriasis Who Initiated Guselkumab in CorEvitas’ Psoriasis Registry. Dermatol Ther (Heidelb), 12(1), 97-119. (Read full article)
25. Stein Gold L, Papp K, Pariser D, Green L, Bhatia N, Sofen H, Albrecht L, Gooderham M, Chen M, Paris M, Wang Y, Callis Duffin K (2022). Efficacy and safety of apremilast in patients with mild-to-moderate plaque psoriasis: Results of a phase 3, multicenter, randomized, double-blind, placebo-controlled trial. J Am Acad Dermatol, 86(1), 77-85. (Read full article)
26. Walsh JA, Callis Duffin K, Van Voorhees AS, Chakravarty SD, Fitzgerald T, Teeple A, Rowland K, Uy J, McLean RR, Malley W, Cronin A, Merola JF (2021). Demographics, Disease Characteristics, and Patient-Reported Outcomes Among Patients with Psoriasis Who Initiated Guselkumab in CorEvitas' Psoriasis Registry. Dermatol Ther (Heidelb), 12(1), 97-119. (Read full article)
27. Taliercio VL, Snyder AM, Biggs AM, Kean J, Hess R, Duffin KC, Cizik AM, Secrest AM (2021). Clinicians' perspectives on the integration of electronic patient-reported outcomes into dermatology clinics: a qualitative study. Qual Life Res, 31(6), 1719-1725. (Read full article)
28. Belman S, Walsh JA, Carroll C, Milliken M, Haaland B, Duffin KC, Krueger GG, Feng BJ (2021). Psoriasis Characteristics for the Early Detection of Psoriatic Arthritis. J Rheumatol, 48(10), 1559-1565. (Read full article)
29. Duffin KC, Gottlieb AB, OSullivan D, Gladman DD, McFarland LV (2021). Prologue: 2020 Annual Meeting of the Group for Research and Assessment of Psoriasis and Psoriatic Arthritis (GRAPPA). J Rheumatol Suppl, 97, 1-3. (Read full article)
30. Mease PJ, Calabrese LH, Duffin KC, Haberman RH, Firmino R, Scher JU, Schick L, Winthrop K, Merola JF (2021). Psoriasis and Psoriatic Arthritis in the Context of the COVID-19 Pandemic: A Plenary Session From the GRAPPA 2020 Annual Meeting. J Rheumatol Suppl, 97, 24-29. (Read full article)
31. Duffin KC, Bachelez H, Mease PJ, Rosen C, Garg A, Zudak E, Elkayam O, Merola JF, Chau J, Kishimoto M, Furer V, Helliwell PS (2021). Pustular Psoriasis and Associated Musculoskeletal Disorders. J Rheumatol Suppl, 97, 34-38. (Read full article)
32. Callis Duffin K, Bachelez H, Mease PJ, Rosen C, Garg A, Zudak E, Elkayam O, Merola J, Chau J, Kishimoto M, Furer V, Helliwell PS (2021). Pustular Psoriasis and Associated Musculoskeletal Disorders. J Rheumatol. (Read full article)
33. Mease PJ, Calabrese LH, Callis Duffin K, Haberman RH, Firmino R, Scher JU, Schick L, Winthrop K, Merola JF (2021). Psoriasis and Psoriatic Arthritis in the Context of the COVID-19 Pandemic: A Plenary Session From the GRAPPA 2020 Annual Meeting. J Rheumatol. (Read full article)
34. Kornmehl H, Callis Duffin K, Salame N, Perez-Chada LM, Singh S, Garg A, Gottlieb AB, Latella J, Merola JF, Armstrong AW (2021). Examination of Treatment Satisfaction Instruments in Psoriasis: 2017 Results from the Psoriasis Working Group of the International Dermatology Outcome Measures (IDEOM). Dermatology, 237(2), 151-157. (Read full article)
35. Leung YY, Orbai AM, Tillett W, Ogdie A, Eder L, Goel N, Hojgaard P, Holland R, Mathew AJ, Lindsay CA, Antony A, Chau J, Christensen R, Coates LC, Mease PJ, Strand V, FitzGerald O, de Wit M, Callis Duffin K, Gladman DD (2021). Instruments Measuring Physical Function for Psoriatic Arthritis Endorsed at GRAPPA 2020 Annual Meeting: Updates of the GRAPPA-OMERACT Working Group. J Rheumatol. (Read full article)
36. Callis Duffin K, Gottlieb AB, OSullivan D, Gladman DD, McFarland LV (2021). Prologue: 2020 Annual Meeting of the Group for Research and Assessment of Psoriasis and Psoriatic Arthritis (GRAPPA). J Rheumatol. (Read full article)
37. Taliercio V, Langner AU, Secrest AM, Duffin KC (2021). Assessing psoriasis severity: psychometric validation of overall physician global assessment (OPGA). J Am Acad Dermatol, 86(3), 637-638. (Read full article)
38. Callis Duffin K, Mason MA, Gordon K, Harrison RW, Crabtree MM, Guana A, Germino R, Lebwohl M (2021). Characterization of Patients with Psoriasis in Challenging-to-Treat Body Areas in the Corrona Psoriasis Registry. Dermatology, 237(1), 46-55. (Read full article)
39. Carlisle RP, Flint ND, Hopkins ZH, Eliason MJ, Duffin KC, Secrest AM (2020). Administrative Burden and Costs of Prior Authorizations in a Dermatology Department. JAMA Dermatol, 156(10), 1074-1078. (Read full article)
40. Gelfand JM, Shin DB, Duffin KC, Armstrong AW, Blauvelt A, Tyring SK, Menter A, Gottlieb S, Lockshin BN, Simpson EL, Kianifard F, Sarkar RP, Muscianisi E, Steadman J, Ahlman MA, Playford MP, Joshi AA, Dey AK, Werner TJ, Alavi A, Mehta NN (2020). A Randomized Placebo-Controlled Trial of Secukinumab on Aortic Vascular Inflammation in Moderate-to-Severe Plaque Psoriasis (VIP-S). J Invest Dermatol, 140(9), 1784-1793.e2. (Read full article)
41. Taliercio V, Langner AU, Secrest AM, Duffin KC (2020). Research Letter Measuring quality in psoriasis: early experiences with the MIPS 410 quality measure-cross sectional study. J Am Acad Dermatol. (Read full article)
42. Waxman R, Stober C, Jadon DR, Orbai AM, Chandran V, Ogdie A, Pennington SR, De Wit M, OSullivan D, Mease PJ, Armstrong AW, Callis Duffin K, Helliwell PS, Van Mens LJJ, Ritchlin CT, FitzGerald O (2020). Proceedings of the 2019 grappa collaborative research network meeting. J Rheumatol, 96, 25-30. (Read full article)
43. Leung YY, Tillett W, Orbai AM, Ogdie A, Eder L, Coates LC, Holland R, Antony A, Goel N, Mease PJ, Strand V, FitzGerald O, De Wit M, Lindsay CA, Duffin KC, Gladman DD (2020). The grappa-omeract working group: 4 prioritized domains for completing the core outcome measurement set for psoriatic arthritis 2019 updates. J Rheumatol, 96, 46-49. (Read full article)
44. Coates LC, Merola JF, Grieb SM, Mease PJ, Duffin KC (2020). Methotrexate in psoriasis and psoriatic arthritis. J Rheumatol, 96, 31-35. (Read full article)
45. Duffin KC, Gladman DD, Goel N, Gottlieb AB (2020). Prologue: 2019 annual meeting of the group for research and assessment of psoriasis and psoriatic arthritis (grappa). J Rheumatol, 96, 1-3. (Read full article)
46. Blauvelt A, Papp K, Gottlieb A, Jarell A, Reich K, Maari C, Gordon KB, Ferris LK, Langley RG, Tada Y, Lima RG, Elmaraghy H, Gallo G, Renda L, Park SY, Burge R, Bagel J, Vender R, Lomaga MA, Delorme I, Hong CH, Langley RL, Albrecht L, Guenther L, Maari C, Papp K, Singh Ohson KK, Barber K, Lynde C, Gupta A, Rosoph L, Gauthier JS, Gooderham M, Wasel N, Raman M, Wiseman M, Greenstein D, Jarell A, Moon C, Clark L, Jazayeri SS, Bukhalo M, Moore A, Hamilton TK, Gewirtzman A, Hazan L, Crowley J, Teller C, Zirwas M, Smith SR, Christine Lee M, Tyring S, Lee P, Dhawan S, Leonardi C, Jesus APD, McFalda W, Frankel E, Yamauchi P, Fretzin S, Serrao R, Schlesinger T, Gottlieb S, Jenkin P, Gharib R, Davis S, Nami N, Draelos ZD, Godwin L, Owen C, Landis M, Abramovits W, Sanchez-Rivera S, Van Voorhees A, Fivenson D, Kerdel F, Forman SB, Weinberg J, Gonzalez-Chavez J, Boyce B, Stein-Gold L, Hudson C, Brown C, Coggi J, Feser C, Forconi R, Johnson S, McCune M, Green L, Madkan V, Shipp DM, Gordon KB, Waibel J, Soto-Raices O, Cather J, Miller S, Scott J, Young D, Kaffenberger J, Yokum K (2020). A head-to-head comparison of ixekizumab vs. guselkumab in patients with moderate-to-severe plaque psoriasis: 12-week efficacy, safety and speed of response from a randomized, double-blinded trial. Br J Dermatol, 182(6), 1348-1358. (Read full article)
47. Perez-Chada LM, Salame NF, Ford AR, Duffin KC, Garg A, Gottlieb AB, Latella J, Merola JF, Armstrong AW (2020). Investigator and Patient Global Assessment Measures for Psoriasis Clinical Trials: A Systematic Review on Measurement Properties from the International Dermatology Outcome Measures (IDEOM) Initiative. Am J Clin Dermatol, 21(3), 323-338. (Read full article)
48. Perez-Chada LM, Gottlieb AB, Cohen J, Mease P, Duffin KC, Garg A, Latella J, Armstrong AW, Ogdie A, Merola JF (2019). Measuring psoriatic arthritis symptoms: A core domain in psoriasis clinical trials. J Am Acad Dermatol, 82(1), 54-61. (Read full article)
49. Noe MH, Wan MT, Shin DB, Armstrong AW, Duffin KC, Chiesa Fuxench ZC, Kalb RE, Menter A, Simpson EL, Takeshita J, Tyring SK, Van Voorhees AS, Mehta NN, Gelfand JM (2019). Patient-reported outcomes of adalimumab, phototherapy, and placebo in the Vascular Inflammation in Psoriasis Trial: A randomized controlled study. J Am Acad Dermatol, 81(4), 923-930. (Read full article)
50. Strober B, van de Kerkhof PCM, Callis Duffin K, Poulin Y, Warren RB, de la Cruz C, van der Walt JM, Stolshek BS, Martin ML, de Carvalho AVE (2019). Feasibility and Utility of the Psoriasis Symptom Inventory (PSI) in Clinical Care Settings: A Study from the International Psoriasis Council. Am J Clin Dermatol, 20(5), 699-709. (Read full article)
51. Perez-Chada L, Taliercio VL, Gottlieb A, Van Beek M, Duffin KC, Reeder M, Merola JF, Swerlick RA (2019). Achieving Consensus on Patient-Reported Outcome Measures in Clinical Practice for Inflammatory Skin Disorders: On Behalf of International Dermatology Outcome Measures and the American Academy of Dermatology. J Am Acad Dermatol, 88(1), 86-93. (Read full article)
52. Callis Duffin K, Bushmakin AG, Cappelleri JC, Mallbris L, Mamolo C (2019). A multi-item Physician Global Assessment scale to assess psoriasis disease severity: validation based on four phase III tofacitinib studies. BMC Dermatol, 19(1), 8. (Read full article)
53. Callis Duffin K, Gladman DD, Gottlieb AB, Goel N (2019). Prologue: 2018 Annual Meeting of the Group for Research and Assessment of Psoriasis and Psoriatic Arthritis (GRAPPA). J Rheumatol Suppl, 95, 1-3. (Read full article)
54. Jadon DR, Chandran V, Ogdie A, Pennington SR, Stober C, Gladman DD, de Wit M, OSullivan D, Mease P, Armstrong AW, Callis Duffin K, Magee C, Helliwell P, Ritchlin CT, FitzGerald O (2019). Proceedings of the 2018 GRAPPA Collaborative Research Network Meeting. J Rheumatol Suppl, 95, 11-19. (Read full article)
55. Leung YY, Orbai AM, Ogdie A, Coates LC, de Wit M, Callis Duffin K, Eder L, Gladman DD, Goel N, Mease PJ, Strand V, FitzGerald O, Tillett W (2019). The GRAPPA-OMERACT Psoriatic Arthritis Working Group at the 2018 Annual Meeting: Report and Plan for Completing the Core Outcome Measurement Set. J Rheumatol Suppl, 95, 33-37. (Read full article)
56. Duffin KC Md Ms (2015). Identifying and Managing Complications and Comorbidities in Patients With Psoriasis. Semin Cutan Med Surg, 34(2 Suppl), S30-3. (Read full article)
57. Duffin KC Md Ms (2015). Screening and Monitoring Before and During Systemic Therapy: Recommendations for Patients With Psoriasis. Semin Cutan Med Surg, 34(2 Suppl), S40-2. (Read full article)
58. Armstrong AW, Parsi K, Schupp CW, Mease PJ, Duffin KC (2013). Standardizing training for psoriasis measures: effectiveness of an online training video on Psoriasis Area and Severity Index assessment by physician and patient raters. JAMA Dermatol, 149(5), 577-82. (Read full article)
59. Walsh JA, Callis Duffin K, Krueger GG, Clegg DO (2013). Limitations in screening instruments for psoriatic arthritis: a comparison of instruments in patients with psoriasis. J Rheumatol, 40(3), 287-93. (Read full article)
60. Yeung H, Wan J, Van Voorhees AS, Callis Duffin K, Krueger GG, Kalb RE, Weisman JD, Sperber BR, Brod BA, Schleicher SM, Bebo BF Jr, Shin DB, Troxel AB, Gelfand JM (2013). Patient-reported reasons for the discontinuation of commonly used treatments for moderate to severe psoriasis. J Am Acad Dermatol, 68(1), 64-72. (Read full article)
61. Jordan CT, Cao L, Roberson ED, Duan S, Helms CA, Nair RP, Duffin KC, Stuart PE, Goldgar D, Hayashi G, Olfson EH, Feng BJ, Pullinger CR, Kane JP, Wise CA, Goldbach-Mansky R, Lowes MA, Peddle L, Chandran V, Liao W, Rahman P, Krueger GG, Gladman D, Elder JT, Menter A, Bowcock AM (2012). Rare and common variants in CARD14, encoding an epidermal regulator of NF-kappaB, in psoriasis. Am J Hum Genet, 90(5), 796-808. (Read full article)
62. Gelfand JM, Wan J, Callis Duffin K, Krueger GG, Kalb RE, Weisman JD, Sperber BR, Stierstorfer MB, Brod BA, Schleicher SM, Bebo BF Jr, Troxel AB, Shin DB, Steinemann JM, Goldfarb J, Yeung H, Van Voorhees AS (2012). Comparative effectiveness of commonly used systemic treatments or phototherapy for moderate to severe plaque psoriasis in the clinical practice setting. Arch Dermatol, 148(4), 487-94. (Read full article)
63. Hsu S, Papp KA, Lebwohl MG, Bagel J, Blauvelt A, Duffin KC, Crowley J, Eichenfield LF, Feldman SR, Fiorentino DF, Gelfand JM, Gottlieb AB, Jacobsen C, Kalb RE, Kavanaugh A, Korman NJ, Krueger GG, Michelon MA, Morison W, Ritchlin CT, Stein Gold L, Stone SP, Strober BE, Van Voorhees AS, Weiss SC, Wanat K, Bebo BF Jr (2012). Consensus guidelines for the management of plaque psoriasis. Arch Dermatol, 148(1), 95-102. (Read full article)
64. Wong B, Machan M, Krueger GG, Callis Duffin K (10/01/11). Increased Prevalence of Sleep Disorders and Medical Comorbidities in Psoriatic Arthritis Patients Compared with Patients With and Without Psoriasis. Psoriasis Forum, 17(3), 209-215.
65. Callis Duffin K, Mease PJ (2011). Psoriasis and Psoriatic Arthritis Video Project 2010: a report from the GRAPPA annual meeting. J Rheumatol, 38(3), 562-3. (Read full article)
66. Narayanan S, Callis-Duffin K, Batten J, Agarwal N (2010). Improvement of psoriasis during sunitinib therapy for renal cell carcinoma. Am J Med Sci, 339(6), 580-1. (Read full article)
67. Duffin KC, Freeny IC, Schrodi SJ, Wong B, Feng BJ, Soltani-Arabshahi R, Rakkhit T, Goldgar DE, Krueger GG (2009). Association between IL13 polymorphisms and psoriatic arthritis is modified by smoking. J Invest Dermatol, 129(12), 2777-83. (Read full article)
68. Feng BJ, Sun LD, Soltani-Arabshahi R, Bowcock AM, Nair RP, Stuart P, Elder JT, Schrodi SJ, Begovich AB, Abecasis GR, Zhang XJ, Callis-Duffin KP, Krueger GG, Goldgar DE (2009). Multiple Loci within the major histocompatibility complex confer risk of psoriasis. PLoS Genet, 5(8), e1000606. (Read full article)
69. Nair RP, Ding J, Duffin KC, Helms C, Voorhees JJ, Krueger GG, Bowcock AM, Abeasis GR, Elder JT (2009). Psoriasis bench to bedside: genetics meets immunology. Arch Dermatol, 145(4), 462-4. (Read full article)
70. Callis Duffin K, Wong B, Horn EJ, Krueger GG (2009). Psoriatic arthritis is a strong predictor of sleep interference in patients with psoriasis. J Am Acad Dermatol, 60(4), 604-8. (Read full article)
71. Grande-Sarpa H, Callis Duffin KP, Florell SR (2008). Onychodystrophy and tumor-stage mycosis fungoides confined to a single digit: report of a case and review of nail findings in cutaneous T-cell lymphoma. J Am Acad Dermatol, 59(1), 154-7. (Read full article)

Review

1. Ball GD, Hamade H, Gottlieb AB, Kirby B, Duffin KC (2024). GRAPPA Point-Counterpoint: Should Biologics Be Used for Mild Psoriasis? [Review]. J Rheumatol, 51(Suppl 2), 39-42. (Read full article)
2. Duffin KC, Thio HB, Helliwell PS (2024). Synovitis, Acne, Pustulosis, Hyperostosis, Osteitis, Palmoplantar Pustulosis, and Neutrophilic Dermatoses: A GRAPPA 2023 Annual Meeting Update. [Review]. J Rheumatol, 51(Suppl 2), 77-79. (Read full article)
3. Choon SE, Van De Kerkhof P, Gudjonsson JE, De La Cruz C, Barker J, Morita A, Romiti R, Affandi AM, Asawanonda P, Burden AD, Gonzalez C, Marrakchi S, Mowla MR, Okubo Y, Oon HH, Terui T, Tsai TF, Callis-Duffin K, Fujita H, Jo SJ, Merola J, Mrowietz U, Puig L, Thai D, Velsquez M, Augustin M, El Sayed M, Navarini AA, Pink A, Prinz J, Turki H, Magalhes R, Capon F, Bachelez H (2024). International Consensus Definition and Diagnostic Criteria for Generalized Pustular Psoriasis from the International Psoriasis Council. [Review]. JAMA Dermatol, 160(7), 758-768. (Read full article)
4. Duffin KC, Mazzuoccolo LD, Cura MJ, Esposito M, Fernandez AP, Gisondi P, Giunta A, Hillary T, Piaserico S, Solomon JA, Merola JF (2022). Treatment of Psoriasis in Patients With Psoriatic Arthritis: An Updated Literature Review Informing the 2021 GRAPPA Treatment Recommendations. [Review]. J Rheumatol, 50(1), 131-143. (Read full article)
5. deShazo RA, Secrest AM, Armstrong AW, Duffin KC (2020). Addressing Hypertension in Patients With Psoriasis: Review and Recommendations. [Review]. J Psoriasis Psoriatic Arthritis. (Read full article)
6. Salame N, Torres J, Sandhu J, Callis Duffin K, Garg A, Gottlieb AB, Latella J, Merola JF, Armstrong AW (2018). Patient-Reported Outcome Measures for Pediatric Psoriasis: A Systematic Review and Critical Appraisal from International Dermatology Outcome Measures (IDEOM). [Review]. Dermatology, 234(3-4), 112-119. (Read full article)

Conference Proceedings

1. Duffin KC, Mease PJ (2015). Psoriasis and psoriatic arthritis educational initiatives: An update from the 2014 GRAPPA annual meeting. In Duffin KC|Mease PJ (Ed.), J Rheumatol, 42(6), 1056-1058. (Read full article)

Editorial

1. Hopkins ZH, Perez Chada LM, Duffin KC (2023). Defining what matters through core outcomes set development: Uniting stakeholder perspectives, empowering patient voices. Br J Dermatol. (Read full article)

Letter

1. Romagosa R, Kerdel F, Shah N, Krueger G, Callis K (2002). Treatment of psoriasis with 6-thioguanine and hepatic venoocclusive disease [6] [Letter to the editor]. J Am Acad Dermatol, 47(6), 970-972. (Read full article)

Other

1. Leung YY, Orbai AM, Tillett W, Ogdie A, Eder L, Goel N, Hojgaard P, Holland R, Mathew AJ, Lindsay CA, Antony A, Chau J, Christensen R, Coates LC, Mease PJ, Strand V, FitzGerald O, de Wit M, Duffin KC, Gladman DD (2021). Instruments Measuring Physical Function for Psoriatic Arthritis Endorsed at GRAPPA 2020 Annual Meeting: Updates of the GRAPPA-OMERACT Working Group. J Rheumatol Suppl (97, pp. 60-63). Canada. (Read full article)

News

• Chair of Department of Dermatology Named at University of Utah
• The Meaning of Many Moles